| CYP21A2 | Hyperandrogenism | 0.838712 | 5 | TRUE | Included in national screening panel | 1 | 1 | 0.935485 | 
    | HBB | Haemoglobin variant | 0.197344 | 17 | TRUE | Included in national screening panel | 0.918184 | 0.918184 | 0.629848 | 
    | MEFV | Neutrophilic dermatosis | 0.752691 | 3 | TRUE | Included in national screening panel | 0.542552 | 0.542552 | 0.626608 | 
    | SGCG | Muscular dystrophy, limb girdle | 1 | 1 | TRUE | Included in national screening panel | 0.236572 | 0.236572 | 0.541943 | 
    | HBD | Haemoglobin variant | 0.967746 | 1 | TRUE | Included in national screening panel | 0.229039 | 0.229039 | 0.524522 | 
    | F2 | Thrombophilia 1 due to thrombin defect | 0.677421 | 1 | TRUE | Included in national screening panel | 0.16094 | 0.16094 | 0.367532 | 
    | ABCA4 | Retinal dystrophy | 0.211982 | 7 | TRUE | Included in national screening panel | 0.397026 | 0.397026 | 0.323009 | 
    | CUBN | Albuminuria, association with | 0.17742 | 8 | TRUE | Included in national screening panel | 0.39329 | 0.39329 | 0.306942 | 
    | HBA1 | Haemoglobin variant | 0.333334 | 3 | TRUE | Included in national screening panel | 0.253599 | 0.253599 | 0.285493 | 
    | ABCA12 | Ichthyosis | 0.483872 | 1 | TRUE | Included in national screening panel | 0.115249 | 0.115249 | 0.262698 | 
    | CD36 | Platelet glycoprotein IV deficiency | 0.188172 | 6 | TRUE | Included in national screening panel | 0.30648 | 0.30648 | 0.259157 | 
    | ITGB3 | Bleeding disorder | 0.451614 | 1 | TRUE | Included in national screening panel | 0.107611 | 0.107611 | 0.245212 | 
    | BCHE | Butyrylcholinesterase deficiency | 0.27957 | 3 | TRUE | Included in national screening panel | 0.214307 | 0.214307 | 0.240412 | 
    | DONSON | Microcephaly | 0.338711 | 2 | TRUE | Included in national screening panel | 0.168675 | 0.168675 | 0.236689 | 
    | HBA2 | Haemoglobin variant | 0.322582 | 2 | TRUE | Included in national screening panel | 0.161698 | 0.161698 | 0.226051 | 
    | CYP1B1 | Glaucoma 3A | 0.258065 | 3 | TRUE | Included in national screening panel | 0.199576 | 0.199576 | 0.222972 | 
    | PAH | Hyperphenylalaninemia | 0.0537636 | 15 | TRUE | Included in national screening panel | 0.300884 | 0.300884 | 0.202036 | 
    | GJB2 | Keratoderma | 0.161291 | 5 | TRUE | Included in national screening panel | 0.223462 | 0.223462 | 0.198593 | 
    | SORD | Neuronopathy, distal hereditary motor, autosomal recessive 8 | 0.35484 | 1 | TRUE | Included in national screening panel | 0.0846583 | 0.0846583 | 0.192731 | 
    | GALNT3 | Tumoral calcinosis | 0.225807 | 2 | TRUE | Included in national screening panel | 0.11556 | 0.11556 | 0.159659 | 
    | PKLR | Pyruvate kinase deficiency | 0.161291 | 3 | TRUE | Included in national screening panel | 0.13081 | 0.13081 | 0.143002 | 
    | MPL | Thrombocytosis, association with | 0.258065 | 1 | TRUE | Included in national screening panel | 0.0616473 | 0.0616473 | 0.140214 | 
    | F7 | Factor VII deficiency | 0.112904 | 4 | TRUE | Included in national screening panel | 0.130816 | 0.130816 | 0.123651 | 
    | COQ9 | Primary coenzyme Q10 deficiency, neonatal onset | 0.225807 | 1 | TRUE | Included in national screening panel | 0.0539641 | 0.0539641 | 0.122701 | 
    | NCF1 | Chronic granulomatous disease | 0.225807 | 1 | TRUE | Included in national screening panel | 0.0539641 | 0.0539641 | 0.122701 | 
    | SLC26A4 | Deafness | 0.0903227 | 5 | TRUE | Included in national screening panel | 0.138933 | 0.138933 | 0.119489 | 
    | AVIL | Nephrotic syndrome | 0.193549 | 1 | TRUE | Included in national screening panel | 0.0462744 | 0.0462744 | 0.105184 | 
    | PIGO | PIGO deficiency | 0.193549 | 1 | TRUE | Included in national screening panel | 0.0462744 | 0.0462744 | 0.105184 | 
    | UFSP2 | ?Hip dysplasia | 0.193549 | 1 | TRUE | Included in national screening panel | 0.0462744 | 0.0462744 | 0.105184 | 
    | ALDH3A2 | Sjogren-Larsson syndrome | 0.0887098 | 4 | TRUE | Included in national screening panel | 0.108123 | 0.108123 | 0.100357 | 
    | KIF1C | Cerebellar ataxia | 0.129032 | 2 | TRUE | Included in national screening panel | 0.0694861 | 0.0694861 | 0.0933046 | 
    | HSPG2 | Scoliosis, idiopathic, association with | 0.0806455 | 4 | TRUE | Included in national screening panel | 0.1002 | 0.1002 | 0.092378 | 
    | TPO | Thyroid dyshormonogenesis 2A | 0.0645164 | 5 | TRUE | Included in national screening panel | 0.107935 | 0.107935 | 0.0905674 | 
    | C7 | Alzheimer disease in Han Chinese, association with | 0.161291 | 1 | TRUE | Included in national screening panel | 0.0385782 | 0.0385782 | 0.0876631 | 
    | AGK | Sengers syndrome | 0.161291 | 1 | TRUE | Included in national screening panel | 0.0385782 | 0.0385782 | 0.0876631 | 
    | C8A | Complement C8 alpha-gamma deficiency | 0.161291 | 1 | TRUE | Included in national screening panel | 0.0385782 | 0.0385782 | 0.0876631 | 
    | ORC6 | Meier-Gorlin syndrome | 0.161291 | 1 | TRUE | Included in national screening panel | 0.0385782 | 0.0385782 | 0.0876631 | 
    | RPGRIP1 | Cone-rod dystrophy 13 | 0.0860216 | 3 | TRUE | Included in national screening panel | 0.0772147 | 0.0772147 | 0.0807375 | 
    | EYS | Retinitis pigmentosa | 0.0368664 | 7 | TRUE | Included in national screening panel | 0.108136 | 0.108136 | 0.0796279 | 
    | BTD | Biotinidase deficiency | 0.00992557 | 13 | TRUE | Included in national screening panel | 0.123722 | 0.123722 | 0.0782036 | 
    | TYR | Albinism, oculocutaneous | 0.0430108 | 6 | TRUE | Included in national screening panel | 0.100407 | 0.100407 | 0.0774485 | 
    | UPB1 | Beta-ureidopropionase deficiency | 0.075269 | 3 | TRUE | Included in national screening panel | 0.0694731 | 0.0694731 | 0.0717915 | 
    | ABCG8 | Sitosterolemia 1 | 0.0752689 | 3 | TRUE | Included in national screening panel | 0.0694342 | 0.0694342 | 0.0717681 | 
    | CCDC40 | Primary ciliary dyskinesia | 0.0967744 | 2 | TRUE | Included in national screening panel | 0.0540419 | 0.0540419 | 0.0711349 | 
    | PCARE | Retinitis pigmentosa 54 | 0.0967743 | 2 | TRUE | Included in national screening panel | 0.0540094 | 0.0540094 | 0.0711154 | 
    | GNE | GNE myopathy | 0.129032 | 1 | TRUE | Included in national screening panel | 0.0308755 | 0.0308755 | 0.0701383 | 
    | GP6 | Absence of collagen-induced platelet activation | 0.129032 | 1 | TRUE | Included in national screening panel | 0.0308755 | 0.0308755 | 0.0701383 | 
    | VDR | Rickets | 0.129032 | 1 | TRUE | Included in national screening panel | 0.0308755 | 0.0308755 | 0.0701383 | 
    | GLDC | Glycine encephalopathy | 0.129032 | 1 | TRUE | Included in national screening panel | 0.0308755 | 0.0308755 | 0.0701383 | 
    | GRM6 | Congenital stationary night blindness | 0.129032 | 1 | TRUE | Included in national screening panel | 0.0308755 | 0.0308755 | 0.0701383 | 
    | PSAP | Combined SAP deficiency | 0.129032 | 1 | TRUE | Included in national screening panel | 0.0308755 | 0.0308755 | 0.0701383 | 
    | PLOD1 | Ehlers-Danlos syndrome | 0.129032 | 1 | TRUE | Included in national screening panel | 0.0308755 | 0.0308755 | 0.0701383 | 
    | PTPRQ | Congenital sensorineural hearing loss, autosomal recessive | 0.129032 | 1 | TRUE | Included in national screening panel | 0.0308755 | 0.0308755 | 0.0701383 | 
    | USH2A | Retinitis Pigmentosa | 0.0201614 | 8 | TRUE | Included in national screening panel | 0.0927886 | 0.0927886 | 0.0637377 | 
    | LAMA1 | Schizophrenia | 0.0645162 | 3 | TRUE | Included in national screening panel | 0.0618028 | 0.0618028 | 0.0628882 | 
    | ABCC6 | Pseudoxanthoma elasticum | 0.0387097 | 5 | TRUE | Included in national screening panel | 0.0772147 | 0.0772147 | 0.0618127 | 
    | RAB3GAP2 | Microphthalmia & cataract | 0.0483872 | 4 | TRUE | Included in national screening panel | 0.0695574 | 0.0695574 | 0.0610893 | 
    | GNRHR | Hypogonadotropic hypogonadism | 0.0806453 | 2 | TRUE | Included in national screening panel | 0.0463392 | 0.0463392 | 0.0600616 | 
    | NR2E3 | Retinitis pigmentosa 37 | 0.0806453 | 2 | TRUE | Included in national screening panel | 0.0463392 | 0.0463392 | 0.0600616 | 
    | RARS2 | Pulmonary arterial hypertension | 0.0806453 | 2 | TRUE | Included in national screening panel | 0.0463392 | 0.0463392 | 0.0600616 | 
    | COL17A1 | Epithelial recurrent erosion dystrophy | 0.0806453 | 2 | TRUE | Included in national screening panel | 0.0463392 | 0.0463392 | 0.0600616 | 
    | CCNO | Ciliary dyskinesia | 0.0806453 | 2 | TRUE | Included in national screening panel | 0.0463132 | 0.0463132 | 0.0600461 | 
    | CDK5RAP2 | Autism spectrum disorder | 0.0806453 | 2 | TRUE | Included in national screening panel | 0.0463132 | 0.0463132 | 0.0600461 | 
    | CDH23 | Usher syndrome | 0.0268818 | 6 | TRUE | Included in national screening panel | 0.0773185 | 0.0773185 | 0.0571438 | 
    | VWF | von Willebrand disease | 0.0403227 | 4 | TRUE | Included in national screening panel | 0.0618093 | 0.0618093 | 0.0532147 | 
    | PJVK | Deafness | 0.0967743 | 1 | TRUE | Included in national screening panel | 0.0231663 | 0.0231663 | 0.0526095 | 
    | ALDOB | Fructose intolerance | 0.0967743 | 1 | TRUE | Included in national screening panel | 0.0231663 | 0.0231663 | 0.0526095 | 
    | CNGB3 | Achromatopsia 3 | 0.0967743 | 1 | TRUE | Included in national screening panel | 0.0231663 | 0.0231663 | 0.0526095 | 
    | GAA | Glycogen storage disease II | 0.0215054 | 6 | TRUE | Included in national screening panel | 0.0695833 | 0.0695833 | 0.0503522 | 
    | MYO5B | Diarrhea 2 | 0.0645162 | 2 | TRUE | Included in national screening panel | 0.0386365 | 0.0386365 | 0.0489884 | 
    | SLC3A1 | Cystinuria | 0.0645162 | 2 | TRUE | Included in national screening panel | 0.0386365 | 0.0386365 | 0.0489884 | 
    | ZFYVE26 | Spastic paraplegia with thin corpus callosum | 0.0645162 | 2 | TRUE | Included in national screening panel | 0.0386365 | 0.0386365 | 0.0489884 | 
    | SLC12A3 | Gitelman syndrome | 0.0322581 | 4 | TRUE | Included in national screening panel | 0.0541002 | 0.0541002 | 0.0453634 | 
    | GYS2 | Glycogen storage disease 0 | 0.0430109 | 3 | TRUE | Included in national screening panel | 0.0463781 | 0.0463781 | 0.0450312 | 
    | SI | Sucrase isomaltase deficiency | 0.0430108 | 3 | TRUE | Included in national screening panel | 0.0463651 | 0.0463651 | 0.0450234 | 
    | GALC | Krabbe disease | 0.0430108 | 3 | TRUE | Included in national screening panel | 0.0463651 | 0.0463651 | 0.0450234 | 
    | CFTR | Cystic fibrosis | 0.0193549 | 5 | TRUE | Included in national screening panel | 0.0541196 | 0.0541196 | 0.0402137 | 
    | SPG7 | Spastic paraplegia | 0.0483872 | 2 | TRUE | Included in national screening panel | 0.0309144 | 0.0309144 | 0.0379035 | 
    | ACADS | Short-chain acyl-CoA-dehydrogenase deficiency | 0.0483872 | 2 | TRUE | Included in national screening panel | 0.0309144 | 0.0309144 | 0.0379035 | 
    | F11 | Factor XI deficiency | 0.0483872 | 2 | TRUE | Included in national screening panel | 0.0309014 | 0.0309014 | 0.0378957 | 
    | ANO5 | Muscular dystrophy, limb girdle 2L | 0.0483872 | 2 | TRUE | Included in national screening panel | 0.0309014 | 0.0309014 | 0.0378957 | 
    | OBSL1 | Cardiomyopathy, dilated | 0.0241936 | 4 | TRUE | Included in national screening panel | 0.0463911 | 0.0463911 | 0.0375121 | 
    | TRIP4 | Spinal muscular atrophy & congenital bone fractures | 0.0241936 | 4 | TRUE | Included in national screening panel | 0.0463911 | 0.0463911 | 0.0375121 | 
    | TTC37 | Fatigue, failure to thrive & diarrhoea | 0.0241936 | 4 | TRUE | Included in national screening panel | 0.0463911 | 0.0463911 | 0.0375121 | 
    | DPYS | Dihydropyrimidinase deficiency | 0.0107527 | 6 | TRUE | Included in national screening panel | 0.0541326 | 0.0541326 | 0.0367807 | 
    | GCDH | Glutaric acidaemia 1 | 0.0322581 | 3 | TRUE | Included in national screening panel | 0.0386495 | 0.0386495 | 0.0360929 | 
    | TTC21B | Bardet-Biedl syndrome | 0.0322581 | 3 | TRUE | Included in national screening panel | 0.0386495 | 0.0386495 | 0.0360929 | 
    | TPRN | Hearing loss | 0.0322581 | 3 | TRUE | Included in national screening panel | 0.0386365 | 0.0386365 | 0.0360851 | 
    | C8B | Primary immunodeficiency disease | 0.0645162 | 1 | TRUE | Included in national screening panel | 0.0154507 | 0.0154507 | 0.0350769 | 
    | SAG | Retinitis pigmentosa, autosomal recessive | 0.0645162 | 1 | TRUE | Included in national screening panel | 0.0154507 | 0.0154507 | 0.0350769 | 
    | APTX | Ataxia | 0.0645162 | 1 | TRUE | Included in national screening panel | 0.0154507 | 0.0154507 | 0.0350769 | 
    | MTRR | Cleft lip with or without cleft palate | 0.0645162 | 1 | TRUE | Included in national screening panel | 0.0154507 | 0.0154507 | 0.0350769 | 
    | PEX6 | Peroxisome biogenesis disorder 4B | 0.0645162 | 1 | TRUE | Included in national screening panel | 0.0154507 | 0.0154507 | 0.0350769 | 
    | PHC1 | Primary microcephaly | 0.0645162 | 1 | TRUE | Included in national screening panel | 0.0154507 | 0.0154507 | 0.0350769 | 
    | PMM2 | Congenital disorder of glycosylation 1a | 0.0645162 | 1 | TRUE | Included in national screening panel | 0.0154507 | 0.0154507 | 0.0350769 | 
    | SBF1 | Charcot-Marie-Tooth disease | 0.0645162 | 1 | TRUE | Included in national screening panel | 0.0154507 | 0.0154507 | 0.0350769 | 
    | SVBP | Neurodevelopmental disorder with ataxia | 0.0645162 | 1 | TRUE | Included in national screening panel | 0.0154507 | 0.0154507 | 0.0350769 | 
    | CERS3 | Ichthyosis | 0.0645162 | 1 | TRUE | Included in national screening panel | 0.0154507 | 0.0154507 | 0.0350769 | 
    | MOCOS | Thiopurine-induced toxicity | 0.0645162 | 1 | TRUE | Included in national screening panel | 0.0154507 | 0.0154507 | 0.0350769 | 
    | PSAT1 | Developmental disorder | 0.0645162 | 1 | TRUE | Included in national screening panel | 0.0154507 | 0.0154507 | 0.0350769 | 
    | CYP4V2 | Retinitis pigmentosa | 0.0645162 | 1 | TRUE | Included in national screening panel | 0.0154507 | 0.0154507 | 0.0350769 | 
    | B3GALT6 | Spondyloepimetaphyseal dysplasia with joint laxity | 0.0645162 | 1 | TRUE | Included in national screening panel | 0.0154507 | 0.0154507 | 0.0350769 | 
    | HSD11B2 | Apparent mineralocorticoid excess | 0.0645162 | 1 | TRUE | Included in national screening panel | 0.0154507 | 0.0154507 | 0.0350769 | 
    | TMEM107 | Oral-facial-digital syndrome | 0.0645162 | 1 | TRUE | Included in national screening panel | 0.0154507 | 0.0154507 | 0.0350769 | 
    | DNAH5 | Primary ciliary dyskinesia | 0.0161291 | 4 | TRUE | Included in national screening panel | 0.0386559 | 0.0386559 | 0.0296452 | 
    | KCNJ1 | Bartter syndrome | 0.0215055 | 3 | TRUE | Included in national screening panel | 0.0309274 | 0.0309274 | 0.0271586 | 
    | ATP2A1 | Autism spectrum disorder | 0.0215055 | 3 | TRUE | Included in national screening panel | 0.0309274 | 0.0309274 | 0.0271586 | 
    | CA5A | Carbonic anhydrase VA deficiency | 0.0215054 | 3 | TRUE | Included in national screening panel | 0.0309209 | 0.0309209 | 0.0271547 | 
    | DPYD | Dihydropyrimidine dehydrogenase deficiency | 0.0215054 | 3 | TRUE | Included in national screening panel | 0.0309209 | 0.0309209 | 0.0271547 | 
    | IL17RA | IL-17RA deficiency with bacterial and fungal infections | 0.0215054 | 3 | TRUE | Included in national screening panel | 0.0309209 | 0.0309209 | 0.0271547 | 
    | PANK2 | Neurodegeneration with brain iron accumulation 1 | 0.0322582 | 2 | TRUE | Included in national screening panel | 0.0231923 | 0.0231923 | 0.0268187 | 
    | DNASE1L3 | Systemic lupus erythematosus 16 | 0.0322582 | 2 | TRUE | Included in national screening panel | 0.0231923 | 0.0231923 | 0.0268187 | 
    | FAH | Tyrosinemia | 0.0322581 | 2 | TRUE | Included in national screening panel | 0.0231858 | 0.0231858 | 0.0268147 | 
    | ADA2 | Sneddon syndrome | 0.0322581 | 2 | TRUE | Included in national screening panel | 0.0231858 | 0.0231858 | 0.0268147 | 
    | SBDS | Shwachman-Diamond syndrome | 0.0322581 | 2 | TRUE | Included in national screening panel | 0.0231858 | 0.0231858 | 0.0268147 | 
    | B3GAT3 | Multiple joint dislocations | 0.0322581 | 2 | TRUE | Included in national screening panel | 0.0231858 | 0.0231858 | 0.0268147 | 
    | CYP11B1 | Steroid-11 beta-hydroxylase deficiency | 0.0322581 | 2 | TRUE | Included in national screening panel | 0.0231858 | 0.0231858 | 0.0268147 | 
    | TMEM138 | Joubert syndrome 16 | 0.0322581 | 2 | TRUE | Included in national screening panel | 0.0231858 | 0.0231858 | 0.0268147 | 
    | TMPRSS3 | Hearing loss | 0.0322581 | 2 | TRUE | Included in national screening panel | 0.0231858 | 0.0231858 | 0.0268147 | 
    | CNGA3 | Achromatopsia 2 | 0.00645164 | 5 | TRUE | Included in national screening panel | 0.0386689 | 0.0386689 | 0.025782 | 
    | TRIOBP | Developmental disorder | 0.00645164 | 5 | TRUE | Included in national screening panel | 0.0386689 | 0.0386689 | 0.025782 | 
    | ALMS1 | Alstrom syndrome | 0 | 6 | TRUE | Included in national screening panel | 0.0386754 | 0.0386754 | 0.0232052 | 
    | LOXHD1 | Deafness | 0 | 6 | TRUE | Included in national screening panel | 0.0386754 | 0.0386754 | 0.0232052 | 
    | ATM | Ataxia-telangiectasia | 0.00806455 | 4 | TRUE | Included in national screening panel | 0.0309338 | 0.0309338 | 0.0217861 | 
    | PKHD1 | Polycystic kidney disease 4 | 0.00806455 | 4 | TRUE | Included in national screening panel | 0.0309338 | 0.0309338 | 0.0217861 | 
    | CEP290 | Leber congenital amaurosis 10 | 0.00806455 | 4 | TRUE | Included in national screening panel | 0.0309338 | 0.0309338 | 0.0217861 | 
    | VPS13B | Cohen syndrome | 0.00806455 | 4 | TRUE | Included in national screening panel | 0.0309338 | 0.0309338 | 0.0217861 | 
    | DYNC2H1 | Asphyxiating thoracic dystrophy | 0.00806455 | 4 | TRUE | Included in national screening panel | 0.0309338 | 0.0309338 | 0.0217861 | 
    | DUOX2 | Hypothyroidism | 0 | 5 | TRUE | Included in national screening panel | 0.0309403 | 0.0309403 | 0.0185642 | 
    | C6 | Inflammatory bowel disease, very early onset | 0.0107527 | 3 | TRUE | Included in national screening panel | 0.0231988 | 0.0231988 | 0.0182204 | 
    | MVK | Hyper-IgD syndrome | 0.0107527 | 3 | TRUE | Included in national screening panel | 0.0231988 | 0.0231988 | 0.0182204 | 
    | AGXT | Hyperoxaluria | 0.0107527 | 3 | TRUE | Included in national screening panel | 0.0231988 | 0.0231988 | 0.0182204 | 
    | ALPL | Odontohypophosphatasia | 0.0107527 | 3 | TRUE | Included in national screening panel | 0.0231988 | 0.0231988 | 0.0182204 | 
    | ATP7B | Wilson disease | 0.0107527 | 3 | TRUE | Included in national screening panel | 0.0231988 | 0.0231988 | 0.0182204 | 
    | CAPN3 | Muscular dystrophy, limb girdle 2A | 0.0107527 | 3 | TRUE | Included in national screening panel | 0.0231988 | 0.0231988 | 0.0182204 | 
    | OTOGL | Hearing impairment | 0.0107527 | 3 | TRUE | Included in national screening panel | 0.0231988 | 0.0231988 | 0.0182204 | 
    | SPG11 | Charcot-Marie-Tooth disease | 0.0107527 | 3 | TRUE | Included in national screening panel | 0.0231988 | 0.0231988 | 0.0182204 | 
    | SPTA1 | Spherocytosis | 0.0107527 | 3 | TRUE | Included in national screening panel | 0.0231988 | 0.0231988 | 0.0182204 | 
    | PCDH15 | Usher syndrome 1 | 0.0107527 | 3 | TRUE | Included in national screening panel | 0.0231988 | 0.0231988 | 0.0182204 | 
    | CPLANE1 | Joubert syndrome | 0.0107527 | 3 | TRUE | Included in national screening panel | 0.0231988 | 0.0231988 | 0.0182204 | 
    | RAX | Microphthalmia | 0.0322582 | 1 | TRUE | Included in national screening panel | 0.00772861 | 0.00772861 | 0.0175404 | 
    | ACO2 | Optic atrophy 9 | 0.0322582 | 1 | TRUE | Included in national screening panel | 0.00772861 | 0.00772861 | 0.0175404 | 
    | AGRN | Congenital myasthenic syndrome with distal muscle weakness & atrophy | 0.0322582 | 1 | TRUE | Included in national screening panel | 0.00772861 | 0.00772861 | 0.0175404 | 
    | ARSB | Mucopolysaccharidosis type VI (Maroteaux-Lamy) | 0.0322582 | 1 | TRUE | Included in national screening panel | 0.00772861 | 0.00772861 | 0.0175404 | 
    | ASPM | Microcephaly 5 | 0.0322582 | 1 | TRUE | Included in national screening panel | 0.00772861 | 0.00772861 | 0.0175404 | 
    | LHX3 | Hypopituitarism and sensorineural hearing loss | 0.0322582 | 1 | TRUE | Included in national screening panel | 0.00772861 | 0.00772861 | 0.0175404 | 
    | ORC4 | Lymphoproliferative disorder | 0.0322582 | 1 | TRUE | Included in national screening panel | 0.00772861 | 0.00772861 | 0.0175404 | 
    | OTOA | Hearing loss | 0.0322582 | 1 | TRUE | Included in national screening panel | 0.00772861 | 0.00772861 | 0.0175404 | 
    | PEX1 | Zellweger syndrome | 0.0322582 | 1 | TRUE | Included in national screening panel | 0.00772861 | 0.00772861 | 0.0175404 | 
    | PGM3 | Fetal alcohol syndrome, predisposition to | 0.0322582 | 1 | TRUE | Included in national screening panel | 0.00772861 | 0.00772861 | 0.0175404 | 
    | PNPO | Pyridoxamine 5'-phosphate oxidase deficiency | 0.0322582 | 1 | TRUE | Included in national screening panel | 0.00772861 | 0.00772861 | 0.0175404 | 
    | POLG | Mitochondrial recessive ataxia syndrome | 0.0322582 | 1 | TRUE | Included in national screening panel | 0.00772861 | 0.00772861 | 0.0175404 | 
    | QDPR | Dihydropteridine reductase deficiency | 0.0322582 | 1 | TRUE | Included in national screening panel | 0.00772861 | 0.00772861 | 0.0175404 | 
    | TPI1 | Hemolytic anemia due to triosephosphate isomerase deficiency | 0.0322582 | 1 | TRUE | Included in national screening panel | 0.00772861 | 0.00772861 | 0.0175404 | 
    | ACAD8 | Isobutyryl-CoA dehydrogenase deficiency | 0.0322582 | 1 | TRUE | Included in national screening panel | 0.00772861 | 0.00772861 | 0.0175404 | 
    | AP4S1 | Spastic paraplegia 52 | 0.0322582 | 1 | TRUE | Included in national screening panel | 0.00772861 | 0.00772861 | 0.0175404 | 
    | ATP9A | Neurodevelopmental disorder with poor growth and behavioral abnormalities | 0.0322582 | 1 | TRUE | Included in national screening panel | 0.00772861 | 0.00772861 | 0.0175404 | 
    | CHRNG | Multiple pterygium syndrome | 0.0322582 | 1 | TRUE | Included in national screening panel | 0.00772861 | 0.00772861 | 0.0175404 | 
    | CNTN2 | Hypogonadotropic hypogonadism | 0.0322582 | 1 | TRUE | Included in national screening panel | 0.00772861 | 0.00772861 | 0.0175404 | 
    | CRIPT | Short stature, microcephaly & dysmorphic facies | 0.0322582 | 1 | TRUE | Included in national screening panel | 0.00772861 | 0.00772861 | 0.0175404 | 
    | DGAT1 | Diarrhea | 0.0322582 | 1 | TRUE | Included in national screening panel | 0.00772861 | 0.00772861 | 0.0175404 | 
    | DGUOK | Portal hypertension | 0.0322582 | 1 | TRUE | Included in national screening panel | 0.00772861 | 0.00772861 | 0.0175404 | 
    | DHODH | Miller syndrome | 0.0322582 | 1 | TRUE | Included in national screening panel | 0.00772861 | 0.00772861 | 0.0175404 | 
    | DNAH9 | Situs inversus and male infertility | 0.0322582 | 1 | TRUE | Included in national screening panel | 0.00772861 | 0.00772861 | 0.0175404 | 
    | DOCK6 | Adams-Oliver syndrome 2 | 0.0322582 | 1 | TRUE | Included in national screening panel | 0.00772861 | 0.00772861 | 0.0175404 | 
    | FANCC | Fanconi anemia | 0.0322582 | 1 | TRUE | Included in national screening panel | 0.00772861 | 0.00772861 | 0.0175404 | 
    | FRAS1 | Congenital anomalies of the kidney and urinary tract | 0.0322582 | 1 | TRUE | Included in national screening panel | 0.00772861 | 0.00772861 | 0.0175404 | 
    | G6PC1 | Glycogen storage disease Ia | 0.0322582 | 1 | TRUE | Included in national screening panel | 0.00772861 | 0.00772861 | 0.0175404 | 
    | GALK1 | Galactokinase deficiency, presenile cataract | 0.0322582 | 1 | TRUE | Included in national screening panel | 0.00772861 | 0.00772861 | 0.0175404 | 
    | GDAP1 | Charcot-Marie-Tooth disease | 0.0322582 | 1 | TRUE | Included in national screening panel | 0.00772861 | 0.00772861 | 0.0175404 | 
    | GIPC3 | Hearing loss, non-syndromic | 0.0322582 | 1 | TRUE | Included in national screening panel | 0.00772861 | 0.00772861 | 0.0175404 | 
    | KLHL7 | Retinitis pigmentosa 42 | 0.0322582 | 1 | TRUE | Included in national screening panel | 0.00772861 | 0.00772861 | 0.0175404 | 
    | LAMA3 | Epidermolysis bullosa, junctional | 0.0322582 | 1 | TRUE | Included in national screening panel | 0.00772861 | 0.00772861 | 0.0175404 | 
    | LOXL3 | Myopia 28 | 0.0322582 | 1 | TRUE | Included in national screening panel | 0.00772861 | 0.00772861 | 0.0175404 | 
    | LRRK1 | Osteosclerotic metaphyseal dysplasia | 0.0322582 | 1 | TRUE | Included in national screening panel | 0.00772861 | 0.00772861 | 0.0175404 | 
    | MALT1 | Immunodeficiency, combined | 0.0322582 | 1 | TRUE | Included in national screening panel | 0.00772861 | 0.00772861 | 0.0175404 | 
    | COL6A2 | Bethlem myopathy 1 | 0.0322582 | 1 | TRUE | Included in national screening panel | 0.00772861 | 0.00772861 | 0.0175404 | 
    | LRPPRC | Infantile mitochondrial disease, lethal | 0.0322582 | 1 | TRUE | Included in national screening panel | 0.00772861 | 0.00772861 | 0.0175404 | 
    | MCIDAS | Ciliary dyskinesia | 0.0322582 | 1 | TRUE | Included in national screening panel | 0.00772861 | 0.00772861 | 0.0175404 | 
    | MMACHC | Methylmalonic aciduria and homocystinuria | 0.0322582 | 1 | TRUE | Included in national screening panel | 0.00772861 | 0.00772861 | 0.0175404 | 
    | PLA2G6 | Infantile neuroaxonal dystrophy | 0.0322582 | 1 | TRUE | Included in national screening panel | 0.00772861 | 0.00772861 | 0.0175404 | 
    | SKIV2L | Macular degeneration, age related, reduced risk | 0.0322582 | 1 | TRUE | Included in national screening panel | 0.00772861 | 0.00772861 | 0.0175404 | 
    | SLC5A7 | Neuronopathy | 0.0322582 | 1 | TRUE | Included in national screening panel | 0.00772861 | 0.00772861 | 0.0175404 | 
    | CFAP410 | Retinitis pigmentosa | 0.0322582 | 1 | TRUE | Included in national screening panel | 0.00772861 | 0.00772861 | 0.0175404 | 
    | COL27A1 | Steel syndrome | 0.0322582 | 1 | TRUE | Included in national screening panel | 0.00772861 | 0.00772861 | 0.0175404 | 
    | EDARADD | Ectodermal dysplasia 11A | 0.0322582 | 1 | TRUE | Included in national screening panel | 0.00772861 | 0.00772861 | 0.0175404 | 
    | IL12RB1 | Mycobacterial infection | 0.0322582 | 1 | TRUE | Included in national screening panel | 0.00772861 | 0.00772861 | 0.0175404 | 
    | SLC6A19 | Hartnup disorder | 0.0322582 | 1 | TRUE | Included in national screening panel | 0.00772861 | 0.00772861 | 0.0175404 | 
    | KIAA0586 | Joubert syndrome | 0.0322582 | 1 | TRUE | Included in national screening panel | 0.00772861 | 0.00772861 | 0.0175404 | 
    | AIRE | Autoimmune polyendocrinopathy syndrome | 0.0161291 | 2 | TRUE | Included in national screening panel | 0.0154637 | 0.0154637 | 0.0157299 | 
    | CDH3 | Hypotrichosis | 0.0161291 | 2 | TRUE | Included in national screening panel | 0.0154637 | 0.0154637 | 0.0157299 | 
    | FTCD | Formiminoglutamic acidura | 0.0161291 | 2 | TRUE | Included in national screening panel | 0.0154637 | 0.0154637 | 0.0157299 | 
    | GAMT | Cerebral creatine deficiency syndrome 2 | 0.0161291 | 2 | TRUE | Included in national screening panel | 0.0154637 | 0.0154637 | 0.0157299 | 
    | LDLR | LDL cholesterol level QTL2 | 0.0161291 | 2 | TRUE | Included in national screening panel | 0.0154637 | 0.0154637 | 0.0157299 | 
    | LIFR | Stuve-Wiedemann syndrome/Schwartz-Jampel type 2 syndrome | 0.0161291 | 2 | TRUE | Included in national screening panel | 0.0154637 | 0.0154637 | 0.0157299 | 
    | OCLN | Pseudo-TORCH syndrome 1 | 0.0161291 | 2 | TRUE | Included in national screening panel | 0.0154637 | 0.0154637 | 0.0157299 | 
    | OTOG | Hearing loss, sensorineural | 0.0161291 | 2 | TRUE | Included in national screening panel | 0.0154637 | 0.0154637 | 0.0157299 | 
    | PYGM | McArdle disease | 0.0161291 | 2 | TRUE | Included in national screening panel | 0.0154637 | 0.0154637 | 0.0157299 | 
    | TGM1 | Ichthyosiform erythroderma, congenital, nonbullous | 0.0161291 | 2 | TRUE | Included in national screening panel | 0.0154637 | 0.0154637 | 0.0157299 | 
    | EXPH5 | Epidermolysis bullosa, junctional | 0.0161291 | 2 | TRUE | Included in national screening panel | 0.0154637 | 0.0154637 | 0.0157299 | 
    | GRHPR | Hyperoxaluria II | 0.0161291 | 2 | TRUE | Included in national screening panel | 0.0154637 | 0.0154637 | 0.0157299 | 
    | IQCB1 | Leber congenital amaurosis | 0.0161291 | 2 | TRUE | Included in national screening panel | 0.0154637 | 0.0154637 | 0.0157299 | 
    | NPHS1 | Nephrotic syndrome | 0.0161291 | 2 | TRUE | Included in national screening panel | 0.0154637 | 0.0154637 | 0.0157299 | 
    | ROGDI | Kohlschütter-Tönz syndrome | 0.0161291 | 2 | TRUE | Included in national screening panel | 0.0154637 | 0.0154637 | 0.0157299 | 
    | TRPM1 | Night blindness | 0.0161291 | 2 | TRUE | Included in national screening panel | 0.0154637 | 0.0154637 | 0.0157299 | 
    | CFAP53 | Dextrocardia and situs disturbances | 0.0161291 | 2 | TRUE | Included in national screening panel | 0.0154637 | 0.0154637 | 0.0157299 | 
    | CORO1A | Haemophagocytic lymphohistiocytosis | 0.0161291 | 2 | TRUE | Included in national screening panel | 0.0154637 | 0.0154637 | 0.0157299 | 
    | SEC23B | Anaemia, dyserythropoietic congenital, type II | 0.0161291 | 2 | TRUE | Included in national screening panel | 0.0154637 | 0.0154637 | 0.0157299 | 
    | ALDH7A1 | Epilepsy | 0.0161291 | 2 | TRUE | Included in national screening panel | 0.0154637 | 0.0154637 | 0.0157299 | 
    | PLEKHG5 | Myopathy | 0.0161291 | 2 | TRUE | Included in national screening panel | 0.0154637 | 0.0154637 | 0.0157299 | 
    | SLC34A1 | ?Fanconi renotubular syndrome 2 | 0.0161291 | 2 | TRUE | Included in national screening panel | 0.0154637 | 0.0154637 | 0.0157299 | 
    | ADAMTS18 | Microcornea, myopic chorioretinal atrophy and telecanthus | 0.0161291 | 2 | TRUE | Included in national screening panel | 0.0154637 | 0.0154637 | 0.0157299 | 
    | RNASEH2A | Aicardi-Goutieres syndrome 4 | 0.0161291 | 2 | TRUE | Included in national screening panel | 0.0154637 | 0.0154637 | 0.0157299 | 
    | SERPINF1 | Osteogenesis imperfecta | 0.0161291 | 2 | TRUE | Included in national screening panel | 0.0154637 | 0.0154637 | 0.0157299 | 
    | SLC25A13 | Intrahepatic cholestasis, neonatal | 0.0161291 | 2 | TRUE | Included in national screening panel | 0.0154637 | 0.0154637 | 0.0157299 | 
    | GBA | Gaucher disease | 0 | 4 | TRUE | Included in national screening panel | 0.0232052 | 0.0232052 | 0.0139231 | 
    | PRG4 | Camptodactyly-arthropathy-coxa vara-pericarditis syndrome | 0 | 4 | TRUE | Included in national screening panel | 0.0232052 | 0.0232052 | 0.0139231 | 
    | TMEM67 | Nephronophthisis 11 | 0 | 4 | TRUE | Included in national screening panel | 0.0232052 | 0.0232052 | 0.0139231 | 
    | TTN | Muscular dystrophy | 0 | 3 | TRUE | Included in national screening panel | 0.0154702 | 0.0154702 | 0.00928209 | 
    | CLN3 | Retinal dystrophy, early-onset | 0 | 3 | TRUE | Included in national screening panel | 0.0154702 | 0.0154702 | 0.00928209 | 
    | NBAS | Bone, connective tissue, liver, immune system & retinal defects | 0 | 3 | TRUE | Included in national screening panel | 0.0154702 | 0.0154702 | 0.00928209 | 
    | OTOF | Deafness, non-syndromic | 0 | 3 | TRUE | Included in national screening panel | 0.0154702 | 0.0154702 | 0.00928209 | 
    | PEPD | Prolidase deficiency | 0 | 3 | TRUE | Included in national screening panel | 0.0154702 | 0.0154702 | 0.00928209 | 
    | RTTN | Primary microcephaly & primordial dwarfism | 0 | 3 | TRUE | Included in national screening panel | 0.0154702 | 0.0154702 | 0.00928209 | 
    | STRC | Deafness, non-syndromic | 0 | 3 | TRUE | Included in national screening panel | 0.0154702 | 0.0154702 | 0.00928209 | 
    | ACADVL | Very long chain acyl-CoA dehydrogenase deficiency | 0 | 3 | TRUE | Included in national screening panel | 0.0154702 | 0.0154702 | 0.00928209 | 
    | COL7A1 | EBD | 0 | 3 | TRUE | Included in national screening panel | 0.0154702 | 0.0154702 | 0.00928209 | 
    | DNAH11 | Ciliary dyskinesia | 0 | 3 | TRUE | Included in national screening panel | 0.0154702 | 0.0154702 | 0.00928209 | 
    | TUBGCP6 | Diaphragmatic hernia | 0 | 3 | TRUE | Included in national screening panel | 0.0154702 | 0.0154702 | 0.00928209 | 
    | AGL | Glycogen storage disease 3 | 0 | 2 | TRUE | Included in national screening panel | 0.00773508 | 0.00773508 | 0.00464105 | 
    | CBS | Homocystinuria | 0 | 2 | TRUE | Included in national screening panel | 0.00773508 | 0.00773508 | 0.00464105 | 
    | HGD | Alkaptonuria | 0 | 2 | TRUE | Included in national screening panel | 0.00773508 | 0.00773508 | 0.00464105 | 
    | PTS | Tetrahydrobiopterin deficiency | 0 | 2 | TRUE | Included in national screening panel | 0.00773508 | 0.00773508 | 0.00464105 | 
    | WRN | Werner syndrome | 0 | 2 | TRUE | Included in national screening panel | 0.00773508 | 0.00773508 | 0.00464105 | 
    | AHI1 | Joubert syndrome | 0 | 2 | TRUE | Included in national screening panel | 0.00773508 | 0.00773508 | 0.00464105 | 
    | ALG1 | Congenital disorder of glycosylation | 0 | 2 | TRUE | Included in national screening panel | 0.00773508 | 0.00773508 | 0.00464105 | 
    | ARSA | Metachromatic leukodystrophy | 0 | 2 | TRUE | Included in national screening panel | 0.00773508 | 0.00773508 | 0.00464105 | 
    | CTNS | Cystinosis | 0 | 2 | TRUE | Included in national screening panel | 0.00773508 | 0.00773508 | 0.00464105 | 
    | CUL7 | 3-M syndrome 1 | 0 | 2 | TRUE | Included in national screening panel | 0.00773508 | 0.00773508 | 0.00464105 | 
    | DOK7 | Fetal akinesia deformation sequence 3 | 0 | 2 | TRUE | Included in national screening panel | 0.00773508 | 0.00773508 | 0.00464105 | 
    | EVC2 | Ellis-van Creveld syndrome | 0 | 2 | TRUE | Included in national screening panel | 0.00773508 | 0.00773508 | 0.00464105 | 
    | GBA2 | Spastic paraplegia | 0 | 2 | TRUE | Included in national screening panel | 0.00773508 | 0.00773508 | 0.00464105 | 
    | HEXA | [Hex A pseudodeficiency] | 0 | 2 | TRUE | Included in national screening panel | 0.00773508 | 0.00773508 | 0.00464105 | 
    | HPS3 | Hermansky-Pudlak syndrome 3 | 0 | 2 | TRUE | Included in national screening panel | 0.00773508 | 0.00773508 | 0.00464105 | 
    | IDUA | Hurler syndrome | 0 | 2 | TRUE | Included in national screening panel | 0.00773508 | 0.00773508 | 0.00464105 | 
    | JAK3 | Immunodeficiency, severe combined | 0 | 2 | TRUE | Included in national screening panel | 0.00773508 | 0.00773508 | 0.00464105 | 
    | LYST | Chediak-Higashi syndrome | 0 | 2 | TRUE | Included in national screening panel | 0.00773508 | 0.00773508 | 0.00464105 | 
    | MKS1 | Parkinson disease, early onset | 0 | 2 | TRUE | Included in national screening panel | 0.00773508 | 0.00773508 | 0.00464105 | 
    | PROC | Thrombophilia 3 due to protein C deficiency | 0 | 2 | TRUE | Included in national screening panel | 0.00773508 | 0.00773508 | 0.00464105 | 
    | RYR1 | Congenital myopathy 1B | 0 | 2 | TRUE | Included in national screening panel | 0.00773508 | 0.00773508 | 0.00464105 | 
    | SACS | Spastic ataxia, Charlevoix-Saguenay | 0 | 2 | TRUE | Included in national screening panel | 0.00773508 | 0.00773508 | 0.00464105 | 
    | UBR1 | Johanson-Blizzard syndrome | 0 | 2 | TRUE | Included in national screening panel | 0.00773508 | 0.00773508 | 0.00464105 | 
    | LINS1 | Intellectual developmental disorder | 0 | 2 | TRUE | Included in national screening panel | 0.00773508 | 0.00773508 | 0.00464105 | 
    | NPHP1 | Nephronophthisis 1 | 0 | 2 | TRUE | Included in national screening panel | 0.00773508 | 0.00773508 | 0.00464105 | 
    | NPHP4 | Nephronophthisis 4 | 0 | 2 | TRUE | Included in national screening panel | 0.00773508 | 0.00773508 | 0.00464105 | 
    | RAPSN | Congenital myasthenic syndrome | 0 | 2 | TRUE | Included in national screening panel | 0.00773508 | 0.00773508 | 0.00464105 | 
    | SCN4A | Paramyotonia congenita | 0 | 2 | TRUE | Included in national screening panel | 0.00773508 | 0.00773508 | 0.00464105 | 
    | THOC6 | Intellectual disability | 0 | 2 | TRUE | Included in national screening panel | 0.00773508 | 0.00773508 | 0.00464105 | 
    | ACADSB | Inborn error of metabolism | 0 | 2 | TRUE | Included in national screening panel | 0.00773508 | 0.00773508 | 0.00464105 | 
    | ADGRV1 | Deafness, non-syndromic, autosomal recessive | 0 | 2 | TRUE | Included in national screening panel | 0.00773508 | 0.00773508 | 0.00464105 | 
    | CCDC39 | Primary ciliary dyskinesia | 0 | 2 | TRUE | Included in national screening panel | 0.00773508 | 0.00773508 | 0.00464105 | 
    | GPR179 | Autism spectrum disorder | 0 | 2 | TRUE | Included in national screening panel | 0.00773508 | 0.00773508 | 0.00464105 | 
    | HGSNAT | Mucopolysaccharidosis type IIIC (Sanfilippo C) | 0 | 2 | TRUE | Included in national screening panel | 0.00773508 | 0.00773508 | 0.00464105 | 
    | INPP5E | Joubert syndrome 1 | 0 | 2 | TRUE | Included in national screening panel | 0.00773508 | 0.00773508 | 0.00464105 | 
    | MYO15A | Deafness, non-syndromic, autosomal recessive | 0 | 2 | TRUE | Included in national screening panel | 0.00773508 | 0.00773508 | 0.00464105 | 
    | SPATA7 | Leber congenital amaurosis 3 | 0 | 2 | TRUE | Included in national screening panel | 0.00773508 | 0.00773508 | 0.00464105 | 
    | CYP27A1 | Cerebrotendinous xanthomatosis | 0 | 2 | TRUE | Included in national screening panel | 0.00773508 | 0.00773508 | 0.00464105 | 
    | DYNC2I1 | Short-rib thoracic dysplasia 8 with or without polydactyly | 0 | 2 | TRUE | Included in national screening panel | 0.00773508 | 0.00773508 | 0.00464105 | 
    | SLC37A4 | Glycogen storage disease 1b | 0 | 2 | TRUE | Included in national screening panel | 0.00773508 | 0.00773508 | 0.00464105 | 
    | TMEM231 | Meckel syndrome | 0 | 2 | TRUE | Included in national screening panel | 0.00773508 | 0.00773508 | 0.00464105 | 
    | ADAMTS17 | Weill-Marchesani syndrome | 0 | 2 | TRUE | Included in national screening panel | 0.00773508 | 0.00773508 | 0.00464105 | 
    | SERPINA1 | Reduced alpha-1-antitrypsin concentration | 0 | 2 | TRUE | Included in national screening panel | 0.00773508 | 0.00773508 | 0.00464105 | 
    | SLC25A20 | Carnitine-acylcarnitine translocase deficiency | 0 | 2 | TRUE | Included in national screening panel | 0.00773508 | 0.00773508 | 0.00464105 | 
    | C5 | Complement C5 deficiency | 0 | 1 | TRUE | Included in national screening panel | 0 | 0 | 0 | 
    | FH | Multiple leiomyomatosis | 0 | 1 | TRUE | Included in national screening panel | 0 | 0 | 0 | 
    | PC | Hyperinsulinism | 0 | 1 | TRUE | Included in national screening panel | 0 | 0 | 0 | 
    | ADA | Adenosine deaminase deficiency | 0 | 1 | TRUE | Included in national screening panel | 0 | 0 | 0 | 
    | ASL | Argininosuccinic aciduria | 0 | 1 | TRUE | Included in national screening panel | 0 | 0 | 0 | 
    | ATR | Pulmonary fibrosis / aplastic anaemia | 0 | 1 | TRUE | Included in national screening panel | 0 | 0 | 0 | 
    | BLM | Breast cancer | 0 | 1 | TRUE | Included in national screening panel | 0 | 0 | 0 | 
    | DSP | Cardiomyopathy, arrhythmogenic right ventricular | 0 | 1 | TRUE | Included in national screening panel | 0 | 0 | 0 | 
    | GHR | Hypogonadotropic hypogonadism | 0 | 1 | TRUE | Included in national screening panel | 0 | 0 | 0 | 
    | IVD | Isovaleric acidemia | 0 | 1 | TRUE | Included in national screening panel | 0 | 0 | 0 | 
    | IYD | Hypothyroidism | 0 | 1 | TRUE | Included in national screening panel | 0 | 0 | 0 | 
    | LPL | Hyperlipidaemia | 0 | 1 | TRUE | Included in national screening panel | 0 | 0 | 0 | 
    | NBN | Breast cancer, male | 0 | 1 | TRUE | Included in national screening panel | 0 | 0 | 0 | 
    | PNP | Nucleoside phosphorylase deficiency | 0 | 1 | TRUE | Included in national screening panel | 0 | 0 | 0 | 
    | POR | Altered function | 0 | 1 | TRUE | Included in national screening panel | 0 | 0 | 0 | 
    | ABAT | GABA-transaminase deficiency | 0 | 1 | NAN | - | 0 | 0 | 0 | 
    | ALG2 | Congenital disorder of glycosylation 1i | 0 | 1 | TRUE | Included in national screening panel | 0 | 0 | 0 | 
    | ALG3 | Congenital disorder of glycosylation | 0 | 1 | TRUE | Included in national screening panel | 0 | 0 | 0 | 
    | ALG8 | Congenital disorder of glycosylation 1h | 0 | 1 | TRUE | Included in national screening panel | 0 | 0 | 0 | 
    | BBS5 | Phenotype modifier | 0 | 1 | TRUE | Included in national screening panel | 0 | 0 | 0 | 
    | BBS7 | Bardet-Biedl syndrome, modifier of | 0 | 1 | TRUE | Included in national screening panel | 0 | 0 | 0 | 
    | BBS9 | Retinitis pigmentosa | 0 | 1 | TRUE | Included in national screening panel | 0 | 0 | 0 | 
    | CCN6 | Pseudorheumatoid dysplasia, progressive | 0 | 1 | TRUE | Included in national screening panel | 0 | 0 | 0 | 
    | CLMP | Congenital short-bowel syndrome | 0 | 1 | TRUE | Included in national screening panel | 0 | 0 | 0 | 
    | COG7 | Schizophrenia | 0 | 1 | TRUE | Included in national screening panel | 0 | 0 | 0 | 
    | CRB1 | Leber congenital amaurosis 8 | 0 | 1 | TRUE | Included in national screening panel | 0 | 0 | 0 | 
    | CRB2 | Congenital nephrosis, Finnish type-like, with cerebral ventriculomegaly & raised alpha-fetoprotein | 0 | 1 | TRUE | Included in national screening panel | 0 | 0 | 0 | 
    | CTSK | Pycnodysostosis | 0 | 1 | TRUE | Included in national screening panel | 0 | 0 | 0 | 
    | DLL3 | Congenital scoliosis | 0 | 1 | TRUE | Included in national screening panel | 0 | 0 | 0 | 
    | ELP1 | Autism spectrum disorder | 0 | 1 | TRUE | Included in national screening panel | 0 | 0 | 0 | 
    | EPG5 | Vici syndrome | 0 | 1 | TRUE | Included in national screening panel | 0 | 0 | 0 | 
    | ESPN | Hearing loss | 0 | 1 | TRUE | Included in national screening panel | 0 | 0 | 0 | 
    | FA2H | Spastic paraplegia 35 | 0 | 1 | TRUE | Included in national screening panel | 0 | 0 | 0 | 
    | FBP1 | Fructose-1,6-bisphosphatase deficiency | 0 | 1 | TRUE | Included in national screening panel | 0 | 0 | 0 | 
    | FIG4 | Amyotrophic lateral sclerosis, sporadic | 0 | 1 | TRUE | Included in national screening panel | 0 | 0 | 0 | 
    | GBE1 | Glycogen storage disease 4 | 0 | 1 | TRUE | Included in national screening panel | 0 | 0 | 0 | 
    | GLB1 | GM1-gangliosidosis | 0 | 1 | TRUE | Included in national screening panel | 0 | 0 | 0 | 
    | GPHN | Hyperekplexia | 0 | 1 | TRUE | Included in national screening panel | 0 | 0 | 0 | 
    | KIF7 | Macrocephaly, multiple epiphyseal dysplasia & facial features | 0 | 1 | TRUE | Included in national screening panel | 0 | 0 | 0 | 
    | LIG4 | Marfan syndrome, early-onset | 0 | 1 | TRUE | Included in national screening panel | 0 | 0 | 0 | 
    | LMNA | Mandibuloacral dysplasia | 0 | 1 | TRUE | Included in national screening panel | 0 | 0 | 0 | 
    | MMUT | Methylmalonic aciduria | 0 | 1 | TRUE | Included in national screening panel | 0 | 0 | 0 | 
    | NCF2 | Chronic granulomatous disease | 0 | 1 | TRUE | Included in national screening panel | 0 | 0 | 0 | 
    | NEK1 | Amyotrophic lateral sclerosis | 0 | 1 | TRUE | Included in national screening panel | 0 | 0 | 0 | 
    | NEK8 | Renal disease with hepatic and cardiac anomalies | 0 | 1 | TRUE | Included in national screening panel | 0 | 0 | 0 | 
    | OPA1 | Optic atrophy plus syndrome | 0 | 1 | TRUE | Included in national screening panel | 0 | 0 | 0 | 
    | PCCB | Propionicacidemia | 0 | 1 | TRUE | Included in national screening panel | 0 | 0 | 0 | 
    | PDP1 | Tourette syndrome | 0 | 1 | TRUE | Included in national screening panel | 0 | 0 | 0 | 
    | PGM1 | Congenital disorder of glycosylation | 0 | 1 | TRUE | Included in national screening panel | 0 | 0 | 0 | 
    | PYGL | Glycogen storage disease 6 | 0 | 1 | TRUE | Included in national screening panel | 0 | 0 | 0 | 
    | RAG1 | Omenn syndrome | 0 | 1 | TRUE | Included in national screening panel | 0 | 0 | 0 | 
    | SGCD | Muscular dystrophy | 0 | 1 | TRUE | Included in national screening panel | 0 | 0 | 0 | 
    | SGSH | Mucopolysaccharidosis type IIIA (Sanfilippo A) | 0 | 1 | TRUE | Included in national screening panel | 0 | 0 | 0 | 
    | TMC1 | Deafness | 0 | 1 | TRUE | Included in national screening panel | 0 | 0 | 0 | 
    | WHRN | Usher syndrome | 0 | 1 | TRUE | Included in national screening panel | 0 | 0 | 0 | 
    | ABCC8 | Hyperinsulinism | 0 | 1 | TRUE | Included in national screening panel | 0 | 0 | 0 | 
    | ACADM | Acyl-CoA dehydrogenase | 0 | 1 | TRUE | Included in national screening panel | 0 | 0 | 0 | 
    | AIPL1 | Leber congenital amaurosis IV | 0 | 1 | TRUE | Included in national screening panel | 0 | 0 | 0 | 
    | ANO10 | Cerebellar ataxia 3 | 0 | 1 | TRUE | Included in national screening panel | 0 | 0 | 0 | 
    | ASAH1 | Spinal muscular atrophy with progressive myoclonic epilepsy | 0 | 1 | TRUE | Included in national screening panel | 0 | 0 | 0 | 
    | BCS1L | GRACILE syndrome | 0 | 1 | TRUE | Included in national screening panel | 0 | 0 | 0 | 
    | C2CD3 | Autism spectrum disorder | 0 | 1 | TRUE | Included in national screening panel | 0 | 0 | 0 | 
    | CABP4 | Retinal dystrophy | 0 | 1 | TRUE | Included in national screening panel | 0 | 0 | 0 | 
    | CENPJ | Intellectual disability | 0 | 1 | TRUE | Included in national screening panel | 0 | 0 | 0 | 
    | CHRNE | Congenital myasthenic syndrome | 0 | 1 | TRUE | Included in national screening panel | 0 | 0 | 0 | 
    | COX15 | Hypertrophic cardiomyopathy, early onset | 0 | 1 | TRUE | Included in national screening panel | 0 | 0 | 0 | 
    | COX20 | Dysarthria, ataxia and sensory neuropathy | 0 | 1 | TRUE | Included in national screening panel | 0 | 0 | 0 | 
    | DARS2 | Leukoencephalopathy with brainstem & spinal cord involvement | 0 | 1 | TRUE | Included in national screening panel | 0 | 0 | 0 | 
    | DOCK8 | Immunodeficiency, primary | 0 | 1 | TRUE | Included in national screening panel | 0 | 0 | 0 | 
    | ECEL1 | Arthrogryposis | 0 | 1 | TRUE | Included in national screening panel | 0 | 0 | 0 | 
    | ECHS1 | Short-chain enoyl-CoA hydratase deficiency | 0 | 1 | TRUE | Included in national screening panel | 0 | 0 | 0 | 
    | ERCC2 | Basal cell carcinoma, reduced risk, association with | 0 | 1 | TRUE | Included in national screening panel | 0 | 0 | 0 | 
    | FBXO7 | Parkinsonism, juvenile | 0 | 1 | TRUE | Included in national screening panel | 0 | 0 | 0 | 
    | GALNS | Mucopolysaccharidosis IVA | 0 | 1 | TRUE | Included in national screening panel | 0 | 0 | 0 | 
    | GFPT1 | Congenital myasthenic syndrome | 0 | 1 | TRUE | Included in national screening panel | 0 | 0 | 0 | 
    | HADHB | Mitochondrial trifunctional protein deficiency | 0 | 1 | TRUE | Included in national screening panel | 0 | 0 | 0 | 
    | ITGB2 | Leukocyte adhesion deficiency | 0 | 1 | TRUE | Included in national screening panel | 0 | 0 | 0 | 
    | ITGB4 | Hirschsprung disease | 0 | 1 | TRUE | Included in national screening panel | 0 | 0 | 0 | 
    | KCNV2 | Retinal cone dystrophy 3B | 0 | 1 | TRUE | Included in national screening panel | 0 | 0 | 0 | 
    | LAMB2 | Pierson syndrome/ nephrotic syndrome type 5 | 0 | 1 | TRUE | Included in national screening panel | 0 | 0 | 0 | 
    | LAMC2 | Epidermolysis bullosa, Herlitz | 0 | 1 | TRUE | Included in national screening panel | 0 | 0 | 0 | 
    | LMAN1 | Factor V and factor VIII deficiency, combined | 0 | 1 | TRUE | Included in national screening panel | 0 | 0 | 0 | 
    | LMBR1 | Triphalangeal thumbs and preaxial polydactyly | 0 | 1 | TRUE | Included in national screening panel | 0 | 0 | 0 | 
    | MPV17 | Mitochondrial DNA depletion syndrome, hepatocerebral | 0 | 1 | TRUE | Included in national screening panel | 0 | 0 | 0 | 
    | MRE11 | Breast cancer | 0 | 1 | TRUE | Included in national screening panel | 0 | 0 | 0 | 
    | NUBPL | Complex I deficiency | 0 | 1 | TRUE | Included in national screening panel | 0 | 0 | 0 | 
    | PDE6B | Retinitis pigmentosa, pericentral | 0 | 1 | TRUE | Included in national screening panel | 0 | 0 | 0 | 
    | PEX12 | Peroxisome biogenesis disorder 3B | 0 | 1 | TRUE | Included in national screening panel | 0 | 0 | 0 | 
    | PEX16 | Peroxisome biogenesis disorder 8B | 0 | 1 | TRUE | Included in national screening panel | 0 | 0 | 0 | 
    | PEX26 | Refsum disease, infantile | 0 | 1 | TRUE | Included in national screening panel | 0 | 0 | 0 | 
    | PHGDH | Neu-Laxova syndrome 1 | 0 | 1 | TRUE | Included in national screening panel | 0 | 0 | 0 | 
    | QARS1 | Microcephaly | 0 | 1 | TRUE | Included in national screening panel | 0 | 0 | 0 | 
    | ROBO3 | Gaze palsy | 0 | 1 | TRUE | Included in national screening panel | 0 | 0 | 0 | 
    | SCN9A | Childhood absence epilepsy | 0 | 1 | TRUE | Included in national screening panel | 0 | 0 | 0 | 
    | SMPD1 | Niemann-Pick disease | 0 | 1 | TRUE | Included in national screening panel | 0 | 0 | 0 | 
    | TMCO1 | Cerebro-facio-thoracic dysplasia | 0 | 1 | TRUE | Included in national screening panel | 0 | 0 | 0 | 
    | TTC7A | Immunodeficiency, combined, with intestinal atresias | 0 | 1 | TRUE | Included in national screening panel | 0 | 0 | 0 | 
    | VARS2 | Mitochondrial encephalopathy | 0 | 1 | TRUE | Included in national screening panel | 0 | 0 | 0 | 
    | VPS53 | Parkinson disease, early onset | 0 | 1 | TRUE | Included in national screening panel | 0 | 0 | 0 | 
    | WDR35 | Short rib-polydactyly syndrome | 0 | 1 | TRUE | Included in national screening panel | 0 | 0 | 0 | 
    | WDR62 | Microcephaly, primary | 0 | 1 | TRUE | Included in national screening panel | 0 | 0 | 0 | 
    | XYLT1 | Desbuquois dysplasia 2 | 0 | 1 | TRUE | Included in national screening panel | 0 | 0 | 0 | 
    | AKR1D1 | Bile acid synthesis defect | 0 | 1 | TRUE | Included in national screening panel | 0 | 0 | 0 | 
    | ANTXR2 | Hyaline fibromatosis syndrome | 0 | 1 | TRUE | Included in national screening panel | 0 | 0 | 0 | 
    | B3GLCT | Peters-Plus syndrome | 0 | 1 | TRUE | Included in national screening panel | 0 | 0 | 0 | 
    | CEP152 | Seckel syndrome | 0 | 1 | TRUE | Included in national screening panel | 0 | 0 | 0 | 
    | CLCNKB | Bartter syndrome | 0 | 1 | TRUE | Included in national screening panel | 0 | 0 | 0 | 
    | DNAAF1 | Neural tube defects | 0 | 1 | TRUE | Included in national screening panel | 0 | 0 | 0 | 
    | DPAGT1 | Congenital disorder of glycosylation 1 | 0 | 1 | TRUE | Included in national screening panel | 0 | 0 | 0 | 
    | EXOSC3 | Pontocerebellar hypoplasia 1 | 0 | 1 | TRUE | Included in national screening panel | 0 | 0 | 0 | 
    | FLVCR1 | Posterior column ataxia & retinitis pigmentosa | 0 | 1 | TRUE | Included in national screening panel | 0 | 0 | 0 | 
    | FRRS1L | Intellectual disability, developmental delay & seizures | 0 | 1 | TRUE | Included in national screening panel | 0 | 0 | 0 | 
    | GNPTAB | Mucolipidosis III alpha/beta | 0 | 1 | TRUE | Included in national screening panel | 0 | 0 | 0 | 
    | IFT140 | Leber congenital amaurosis | 0 | 1 | TRUE | Included in national screening panel | 0 | 0 | 0 | 
    | MMADHC | Homocystinuria, cblD type | 0 | 1 | TRUE | Included in national screening panel | 0 | 0 | 0 | 
    | MPLKIP | Trichothiodystrophy, nonphotosensitive | 0 | 1 | TRUE | Included in national screening panel | 0 | 0 | 0 | 
    | NDUFS1 | Neurodevelopmental disorder | 0 | 1 | TRUE | Included in national screening panel | 0 | 0 | 0 | 
    | NKX6-2 | Spastic ataxia 8 | 0 | 1 | TRUE | Included in national screening panel | 0 | 0 | 0 | 
    | PRUNE1 | Hypotonia, microcephaly and global developmental delay | 0 | 1 | TRUE | Included in national screening panel | 0 | 0 | 0 | 
    | RECQL4 | Baller-Gerold syndrome | 0 | 1 | TRUE | Included in national screening panel | 0 | 0 | 0 | 
    | RFXANK | MHC class II deficiency | 0 | 1 | TRUE | Included in national screening panel | 0 | 0 | 0 | 
    | SLC2A1 | Glucose transporter type 1 deficiency syndrome | 0 | 1 | TRUE | Included in national screening panel | 0 | 0 | 0 | 
    | TSEN54 | Intellectual disability & epilepsy | 0 | 1 | TRUE | Included in national screening panel | 0 | 0 | 0 | 
    | VPS33B | Arthrogryposis, renal dysfunction and cholestasis | 0 | 1 | TRUE | Included in national screening panel | 0 | 0 | 0 | 
    | ATP13A2 | Kufor-Rakeb syndrome | 0 | 1 | TRUE | Included in national screening panel | 0 | 0 | 0 | 
    | CCDC103 | Primary ciliary dyskinesia | 0 | 1 | TRUE | Included in national screening panel | 0 | 0 | 0 | 
    | CNTNAP1 | Hypomyelinating neuropathy | 0 | 1 | TRUE | Included in national screening panel | 0 | 0 | 0 | 
    | COL18A1 | Knobloch syndrome | 0 | 1 | TRUE | Included in national screening panel | 0 | 0 | 0 | 
    | FAM161A | Retinitis pigmentosa | 0 | 1 | TRUE | Included in national screening panel | 0 | 0 | 0 | 
    | FOXRED1 | Complex I deficiency | 0 | 1 | TRUE | Included in national screening panel | 0 | 0 | 0 | 
    | HSD17B3 | Pseudohermaphroditism, male | 0 | 1 | TRUE | Included in national screening panel | 0 | 0 | 0 | 
    | HSD17B4 | D-bifunctional protein deficiency | 0 | 1 | TRUE | Included in national screening panel | 0 | 0 | 0 | 
    | MAPKBP1 | Nephronophthisis, late onset | 0 | 1 | TRUE | Included in national screening panel | 0 | 0 | 0 | 
    | NDUFAF5 | Leigh syndrome/Mitochondrial Complex I deficiency | 0 | 1 | TRUE | Included in national screening panel | 0 | 0 | 0 | 
    | SEPSECS | Cerebellar atrophy | 0 | 1 | TRUE | Included in national screening panel | 0 | 0 | 0 | 
    | SLC19A3 | Wernicke's-like encephalopathy | 0 | 1 | TRUE | Included in national screening panel | 0 | 0 | 0 | 
    | SLC22A5 | Carnitine deficiency | 0 | 1 | TRUE | Included in national screening panel | 0 | 0 | 0 | 
    | SLC35D1 | Schneckenbecken dysplasia | 0 | 1 | TRUE | Included in national screening panel | 0 | 0 | 0 | 
    | SLC38A8 | Foveal hypoplasia, optic nerve decussation defects and anterior segment dysgenesis | 0 | 1 | TRUE | Included in national screening panel | 0 | 0 | 0 | 
    | TMEM237 | Joubert syndrome related disorder | 0 | 1 | TRUE | Included in national screening panel | 0 | 0 | 0 | 
    | TRAPPC9 | Hypogonadotropic hypogonadism, normosmic | 0 | 1 | TRUE | Included in national screening panel | 0 | 0 | 0 | 
    | TRMT10A | Neurodevelopmental disorder | 0 | 1 | TRUE | Included in national screening panel | 0 | 0 | 0 | 
    | XPNPEP3 | NPHP-like kidney disease | 0 | 1 | TRUE | Included in national screening panel | 0 | 0 | 0 | 
    | ADAMTS13 | Reduced expression | 0 | 1 | TRUE | Included in national screening panel | 0 | 0 | 0 | 
    | B3GALNT2 | Muscular dystrophy-dystroglycanopathy | 0 | 1 | TRUE | Included in national screening panel | 0 | 0 | 0 | 
    | B4GALNT1 | Spastic paraplegia | 0 | 1 | TRUE | Included in national screening panel | 0 | 0 | 0 | 
    | PRICKLE1 | Neural tube defects | 0 | 1 | TRUE | Included in national screening panel | 0 | 0 | 0 | 
    | RNASEH2B | Aicardi-Goutières syndrome | 0 | 1 | TRUE | Included in national screening panel | 0 | 0 | 0 | 
    | RNASEH2C | Aicardi-Goutieres syndrome 3 | 0 | 1 | TRUE | Included in national screening panel | 0 | 0 | 0 | 
    | SLC25A19 | Thiamine metabolism dysfunction syndrome 4 | 0 | 1 | TRUE | Included in national screening panel | 0 | 0 | 0 | 
    | SLC39A14 | ?Hyperostosis cranalis interna | 0 | 1 | TRUE | Included in national screening panel | 0 | 0 | 0 |